Selling Your Business Through Cyprus: Capital Gains, Exit Tax & Structuring (2026)

The CGT Exemption: What Is Free and What Is Not

The Cipro CGT exemption on share disposals is one of the most powerful and commercially relevant features of the Cipro tax system. It is not a niche provision — it is a general rule that applies to virtually all share disposals by both companies and individuals.

EXEMPT from Cipro CGT: gains on the disposal of shares in any company (Cipro-incorporated or foreign-incorporated); gains on the disposal of debentures and bonds; gains on the disposal of rights over shares (including options and warrants); and gains on securities disposals by individuals. The exemption applies regardless of the size of the gain, the holding period, and the residence status of the seller.

NOT EXEMPT (Cipro CGT applies): gains on the direct disposal of Cipro immovable property (land and buildings physically located in Cipro) — CGT at 20% applies; gains on the disposal of shares in companies where Cipro immovable property constitutes more than 20% of the company's total asset value (this threshold was reduced from 50% as part of the 2026 tax reform — an important change for any company with Cipro real estate exposure).

The immovable property exception requires careful monitoring. Where a holding company owns, directly or indirectly, Cipro land or buildings that represent more than 20% of total consolidated asset value, the shares in that company lose their CGT-exempt status. Companies with mixed portfolios (trading assets and Cipro real estate) should regularly revalue assets to check whether the 20% threshold is being approached.

For the vast majority of Cipro holding companies that hold shares in foreign operating companies, technology businesses, service businesses, or financial assets — and which have no Cipro real estate — the CGT exemption applies in full and unconditionally.

The CGT exemption applies at every level of the ownership chain. If a Cipro holding company sells shares in a foreign subsidiary, 0% CGT. If the individual shareholders of the Cipro holding company then sell their shares in the Cipro holding company, 0% CGT at the individual level as well (subject to the individual's home country tax rules — see individual relocation section below).

Structure: Cyprus Holding Company as the Vehicle for Sale

The most common structure for accessing the Cipro CGT exemption is a straightforward two-tier holding structure: the founder or investor owns a Cipro HoldCo Ltd, which in turn owns the operating company (which may be incorporated in the UK, Germany, USA, Netherlands, or any other jurisdiction). The Cipro HoldCo is the vehicle through which the exit is executed.

On a sale, the buyer acquires the shares of Cipro HoldCo. Cipro HoldCo recognises the gain on the sale of its underlying holding (if it owned shares in the operating company directly) — 0% CGT. Alternatively, the buyer acquires Cipro HoldCo's shares directly from the founder — 0% CGT at the Cipro HoldCo level, and 0% CGT at the individual founder level (as a Cipro tax resident).

After the sale, 100% of the proceeds sit in Cipro HoldCo (if the sale was of the underlying OpCo) or are received directly by the founder (if HoldCo shares were sold). Either way, the full gain is retained without any Cipro CGT leakage.

Distribution of proceeds from Cipro HoldCo to the individual founder post-sale: this is a dividend, and the tax treatment depends on whether the founder is a Cipro non-domiciled resident or a Cipro-domiciled resident.

The following table compares the after-tax outcome of a €10 million gain under different ownership and jurisdiction scenarios:

Share Sale vs Asset Sale: Tax Implications

In practice, a buyer and seller will often have divergent tax preferences as to the structure of the transaction: share sale or asset sale. The seller almost invariably prefers a share sale (which benefits from the Cipro CGT exemption at 0%); the buyer often prefers an asset sale (which allows them to step up the tax basis of acquired assets to market value, generating higher future depreciation and amortisation deductions).

This tension is a standard feature of M&A negotiations and the resolution typically depends on the relative bargaining positions of the parties and the size of the tax benefit to each.

Tax treatment of a share sale through Cipro HoldCo: Cipro HoldCo sells shares in OpCo → 0% CGT; proceeds are participation-exempt dividends or capital returns at HoldCo level; distribution to founder per imposta speciale di difesa/GHS rules above. Total effective tax on the gain at individual level: 0% (non-dom) to approximately 5% (domiciled).

Tax treatment of an asset sale: OpCo sells its assets (business assets, IP, goodwill, customer contracts) to the buyer → gain on asset disposal taxed at OpCo level at the OpCo's jurisdiction corporate tax rate (not Cipro imposta societaria, as the OpCo may be a UK or German company); proceeds sit in OpCo as cash; OpCo distributes to Cipro HoldCo as dividend: participation exemption should apply; Cipro HoldCo distributes to founder: imposta speciale di difesa/GHS as above. The key difference is the imposta societaria bite at OpCo level on the asset gain.

Example: OpCo is a UK company. Asset gain of €10 million. UK corporation tax (25%) on asset gain = €2.5 million. Net after imposta societaria: €7.5 million distributed to Cipro HoldCo (UK dividend WHT: 0%). Cipro HoldCo distributes to non-dom founder: 0% imposta speciale di difesa, minimal GHS. Total after-tax: ~€7.5 million vs €10 million in a share sale. The share sale structure is worth €2.5 million more to the seller in this example.

Pre-Sale Restructuring: Inserting a Cyprus Holding Company

What if the operational business is not already owned through a Cipro holding company at the time of a potential sale? It is often possible to insert a Cipro HoldCo above the existing business before the sale, thereby accessing the CGT exemption. However, this requires careful planning and lead time.

The standard route is a share-for-share exchange: the founder (or existing shareholders of OpCo) exchange their shares in OpCo for shares in a newly incorporated Cipro HoldCo. Cipro HoldCo issues its shares to the founder in exchange for the founder transferring the OpCo shares to Cipro HoldCo. At the completion of the exchange, Cipro HoldCo owns 100% of OpCo, and the founder owns 100% of Cipro HoldCo.

A share-for-share exchange is generally structured to be tax-neutral in the jurisdiction of the operating company. In the EU, this is facilitated by the EU Merger (Reorganisation) Directive, which provides for tax deferral on cross-border share-for-share exchanges within the EU. In the UK, Business Asset Roll-over Relief (BADR) and HMRC's Exchange of Securities rules may provide similar deferral. In the US, an IRC Section 368 reorganisation may be relevant. Each jurisdiction has its own rules and conditions — specialist tax advice in the OpCo's home jurisdiction is essential.

Key risks and considerations for pre-sale restructuring:

Anti-abuse risk: if the restructuring is carried out shortly before a known or anticipated sale, tax authorities in the OpCo's home jurisdiction may challenge the exchange as a scheme to avoid CGT, applying their domestic anti-avoidance rules or the EU GAAR. The closer in time the restructuring is to the sale, the greater the risk.

Minimum holding period: most advisers recommend that the Cipro HoldCo should hold the OpCo shares for at least 12 to 24 months before any sale is executed. This demonstrates that the restructuring was not motivated purely by the upcoming transaction. Two years of genuine HoldCo activity (board meetings in Cipro, management decisions at Cipro level, substance) significantly strengthens the position.

Substance at HoldCo level: the Cipro HoldCo should have genuine economic substance from the moment of incorporation. This means: a Cipro-resident director actively involved in the management of the HoldCo; board meetings held in Cipro at which real decisions are made and minuted; a registered office and bank account in Cipro; and appropriate corporate governance records maintained.

1. Incorporate Cyprus HoldCo Ltd at least 12-24 months before the anticipated exit. Ensure the HoldCo has a Cyprus-resident director and a Cyprus registered office from day one.
2. Obtain tax advice in the OpCo's home jurisdiction regarding the tax treatment of the share-for-share exchange — confirm that a tax-neutral exchange is available and identify any conditions or elections required.
3. Execute the share-for-share exchange: the founder transfers OpCo shares to Cyprus HoldCo; Cyprus HoldCo issues its shares to the founder. Document the exchange with a formal share purchase agreement and resolution.
4. Notify the relevant tax authority in the OpCo's home jurisdiction of the exchange, if required. In the UK, HMRC clearance under Section 138 TCGA 1992 is strongly recommended before executing the exchange.
5. Establish HoldCo substance: appoint a Cyprus-resident director; hold quarterly board meetings in Cyprus; open a Cyprus bank account; maintain management accounts at HoldCo level; ensure OpCo management fee or dividend flows to HoldCo.
6. After the minimum holding period and with genuine substance established, proceed with the sale of Cyprus HoldCo shares (or OpCo shares held by HoldCo) to the buyer.

Individual Relocation to Cyprus Before a Sale

An alternative or complementary strategy to using a Cipro holding company is for the founder to personally relocate to Cipro as a tax resident before the sale crystallises. As a Cipro tax resident, the founder's gain on a share disposal is subject to Cipro CGT — which is 0% on shares.

For this strategy to be effective, the founder must: (a) break tax residency in their home country before the gain arises; and (b) be a Cipro tax resident at the point of sale.

Cipro tax residency is established by spending more than 183 days in Cipro in a tax year. Alternatively, under the Cipro '60-day rule', an individual can establish Cipro tax residency by spending at least 60 days in Cipro, not being tax resident in any other country for more than 183 days, not being tax resident in any other single country, having a permanent residence (owned or rented) in Cipro, and having a connection to Cipro through employment or business.

Home country exit taxes and departure considerations vary significantly by jurisdiction:

Germany: Germany imposes an exit tax (Wegzugsteuer) under Section 6 AStG on individuals holding more than 1% of a company's shares at the time of departure from Germany. The exit tax is calculated on the unrealised gain at the point of departure. Installment options exist for EU/EEA destination moves. This is a critical issue for German founders — take specialist German tax advice before relocating.

Netherlands: the Netherlands has a similar exit tax (conservatoire aanslag) for substantial shareholding holders (5%+ ownership) departing to non-EU countries. Departure to Cipro (an EU member state) benefits from deferral provisions. Specific conditions apply.

France: France imposes an exit tax on departing shareholders holding 50%+ of a company or shares with market value above €800,000. Deferral is available for EU/EEA moves. New treaty with Cipro pending ratification — take Franco-Cypriot tax advice.

UK: the UK does not impose an exit tax on individuals departing the UK. Once non-UK resident, a UK individual is generally not subject to UK CGT on non-UK assets (overseas gains). However, the Temporary Non-Residence rules mean that a UK individual who returns to the UK within 5 years of departure can be taxed on gains that arose during the absence. Founders must therefore plan to remain non-UK resident for at least 5 years if they have left the UK with large unrealised gains.

Minimum time in Cipro: the founder should spend sufficient time in Cipro to both establish genuine Cipro tax residency and genuinely break tax residency in the home country. Attempting to claim Cipro tax residency for one calendar year while still spending substantial time in the home country invites challenge from both tax authorities.

ATAD Corporate Exit Tax: For Companies Transferring Out of Cyprus

The exit tax discussed in the preceding sections concerns the tax position of the individual on departure from their home country. A separate, distinct exit tax applies at the corporate level when a Cipro company transfers assets out of Cipro — this is the ATAD (Anti-Tax Avoidance Directive) exit tax, implemented in Cipro domestic law.

The ATAD exit tax is triggered by: the transfer of assets from a Cipro permanent establishment to a head office or another PE outside Cipro (where Cipro loses the right to tax the transferred assets); the transfer of the tax residence of a Cipro company to another jurisdiction (redomiciliation); and transfers of a business from a Cipro PE to a related entity outside Cipro.

The exit tax is calculated on the difference between the market value of the transferred assets at the point of transfer and their tax book value in Cipro (i.e., the cost or TWDV for capital allowance purposes). The resulting deemed gain is subject to Cipro corporate income tax at the current rate (15% from 2026).

For transfers to EU or EEA member states, Cipro offers a 5-year installment payment option. Rather than paying the entire exit tax liability immediately, the company can pay the tax in five equal annual installments, subject to interest charges and potentially the provision of security (guarantee or charge over assets). Certain events accelerate the installment payment — for example, if the transferred assets are subsequently sold within the 5-year period.

For transfers to third countries outside the EU/EEA, the exit tax is due immediately, with no installment option.

When is the corporate ATAD exit tax relevant to a business sale? It becomes relevant if, following the sale of the business and the receipt of proceeds by Cipro HoldCo, the shareholders decide to redomicile Cipro HoldCo to another jurisdiction (for example, to move the HoldCo to the UAE or Singapore). That redomiciliation would trigger the ATAD exit tax on the accumulated retained earnings and any unrealised asset gains held within Cipro HoldCo at the time of transfer.

For most founders who simply want to retain proceeds in Cipro HoldCo for reinvestment, or extract them as dividends to personal accounts, the ATAD exit tax is not triggered — it is only triggered by the physical transfer of assets or the corporate seat out of Cipro.